文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

巴西7年全国视角:肠杆菌目、铜绿假单胞菌与鲍曼不动杆菌复合群质粒介导碳青霉烯耐药及2019冠状病毒病大流行对其发生的影响

A 7-Year Brazilian National Perspective on Plasmid-Mediated Carbapenem Resistance in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex and the Impact of the Coronavirus Disease 2019 Pandemic on Their Occurrence.
PubMed 文献 · Clin Infect Dis · 2023-01-01

基于巴西抗菌药物耐药监测网络,分析2015—2022年医院碳青霉烯酶检出趋势,并比较COVID-19大流行前后检出情况。肠杆菌目blaKPC检出率68.6%、blaNDM 14.4%,铜绿假单胞菌blaNDM检出率2.5%。肠杆菌目blaNDM年增41.1%、blaKPC年降4.0%,铜绿假单胞菌blaNDM年增71.6%、blaKPC年增22.2%。

要点

  • 肠杆菌目blaKPC检出率68.6%(41301/60205),blaNDM检出率14.4%(8377/58172)。
  • 铜绿假单胞菌blaNDM检出率2.5%(313/12528)。
  • 肠杆菌目blaNDM年增41.1%、blaKPC年降4.0%;铜绿假单胞菌blaNDM年增71.6%、blaKPC年增22.2%。

核心结论

  • 研究显示巴西抗菌药物耐药监测网络在碳青霉烯酶数据方面的优势,并显示COVID-19影响下碳青霉烯酶谱变化,blaNDM逐年上升。

研究设计与样本

  • 基于巴西抗菌药物耐药监测网络,评估纳入公共实验室信息系统的巴西医院碳青霉烯酶检测数据。
  • 检出率定义为每年每株分离菌经基因检测检出碳青霉烯酶的比率。
  • 采用Prais-Winsten回归模型估计时间趋势,用χ2检验比较2017年10月至2020年3月与大流行开始后2020年4月至2022年9月的检出情况,分析期为2015—2022年,使用Stata 17.0软件分析。

主要发现

  • 所有微生物共检测83282株blaKPC和86038株blaNDM。
  • 肠杆菌目blaKPC检出率68.6%(41301/60205),blaNDM检出率14.4%(8377/58172)。
  • 铜绿假单胞菌blaNDM检出率2.5%(313/12528)。
  • 肠杆菌目blaNDM年增41.1%、blaKPC年降4.0%;铜绿假单胞菌blaNDM年增71.6%、blaKPC年增22.2%。
  • 2020至2022年,总分离菌中肠杆菌目增加65.2%、鲍曼不动杆菌复合群增加77.7%、铜绿假单胞菌增加61.3%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carbapenemase production is a global public health threat. Antimicrobial resistance (AMR) data analysis is critical to public health policy. Here we analyzed carbapenemase detection trends using the AMR Brazilian Surveillance Network. METHODS: Carbapenemase detection data from Brazilian hospitals included in the public laboratory information system dataset were evaluated. The detection rate (DR) was defined as carbapenemase detected by gene tested per isolate per year. The temporal trends were estimated using the Prais-Winsten regression model. The impact of COVID-19 on carbapenemase genes in Brazil was determined for the period 2015-2022. Detection pre- (October 2017 to March 2020) and post-pandemic onset (April 2020 to September 2022) was compared using the χ2 test. Analyses were performed with Stata 17.0 (StataCorp, College Station, TX). RESULTS: 83 282 blaKPC and 86 038 blaNDM were tested for all microorganisms. Enterobacterales DR for blaKPC and blaNDM was 68.6% (41 301/60 205) and 14.4% (8377/58 172), respectively. P. aeruginosa DR for blaNDM was 2.5% (313/12 528). An annual percent increase for blaNDM of 41.1% was observed, and a decrease for blaKPC of -4.0% in Enterobacterales, and an annual increase for blaNDM of 71.6% and for blaKPC of 22.2% in P. aeruginosa. From 2020 to 2022, overall increases of 65.2% for Enterobacterales, 77.7% for ABC, and 61.3% for P. aeruginosa were observed in the total isolates. CONCLUSIONS: This study shows the strengths of the AMR Brazilian Surveillance Network with robust data related to carbapenemases in Brazil and the impact of COVID-19 with a change in carbapenemase profiles with blaNDM rising over the years.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kiffer CRV, Rezende TFT, Costa-Nobre DT, et al. A 7-Year Brazilian National Perspective on Plasmid-Mediated Carbapenem Resistance in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex and the Impact of the Coronavirus Disease 2019 Pandemic on Their Occurrence. Clin Infect Dis. 2023. PMID: 37406041. doi:10.1093/cid/ciad260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。